<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/568623A0-5B6C-4FE0-8C3C-F8A2951446E4"><gtr:id>568623A0-5B6C-4FE0-8C3C-F8A2951446E4</gtr:id><gtr:firstName>Christian</gtr:firstName><gtr:otherNames>Hermann</gtr:otherNames><gtr:surname>Ottensmeier</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G1002672"><gtr:id>CF123314-8CD8-436D-91A9-E02D8F34D4BC</gtr:id><gtr:title>A novel anti Wilms-Tumour-1 (WT1) vaccination strategy in haematological malignancy using DNA fusion vaccines deliv</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G1002672</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Scientific Abstract In patients with chronic myeloid leukaemia (CML), while outcome has improved with novel agents such as tyrosine kinase inhibitors, the only curative approach is with allogeneic transplantation. This exerts its benefit through immune control of the cancer, but is only suitable for a small number of patients. This study intends to examine whether DNA vaccination can exert measurable immune control of CML, by assessing disease with the established, clinically relevant monitoring of BCR-ABL transcripts and correlating reduction in BCR-ABL transcript levels (primary endpoint: molecular response rate at 6 months) with responses in WT1 transcript levels and immunological responses (secondary endpoints). We are in clinical testing with a strategy to raise epitope-specific immunity against cancer using a plasmid-DNA fusion vaccine platform. The unique design encodes an immune alert domain (DOM) from tetanus, linked to a tumour antigen-derived epitope (p-DOM-epitope). In the laboratory this design confers tumour protection, breaks immunological tolerance, and induces strong and durable cytotoxic CD8+ T cell immune responses, superior to peptide vaccines. In patients with prostate cancer, 60% (19/31) developed vaccine induced PSMA (prostate specific membrane antigen) specific T cells with excellent vaccine safety. In this same trial a novel delivery system (intramuscular electroporation) enhanced immune responses to the DNA vaccine. We now wish to show that DNA fusion vaccination can control haematological malignancies, specifically CML. Here, escape from cytotoxic T cell attack by loss of MHC I molecules is less likely and molecular markers are already used to guide clinical management. We intend to exploit the high expression of the WT1 antigen in CML and build on the observation that in spite of inducing only transient immunity, even the suboptimal vaccination with peptide vaccines against WT1 conferred some clinical benefit. Our strategy is to use double DNA vaccination targeting two separate WT1-derived peptides. In this phase I/II study we propose to vaccinate up to 37 HLA A0201+ patients with CML in cytogenetic remission (CCyR), stable on imatinib, with 6x 1-monthly doses of two WT1 vaccines, followed by maintenance vaccination up to 2 years in responders. As the vaccine can only work by stimulating the immune system, we intend to show that molecular clinical responses are related to a CD8+ T cell response induced by vaccination, measured by tetramer and ELISPOT analysis. Synchronously, a consented control group of up to 55 patients will be recruited, who are found to be HLA A2 negative at screening (genetic randomiztion). The generated data will assess the clinical response rate, validate WT1 measurement by qPCR as a biomarker for vaccine responses in CML and inform whether definitive Phase III testing of the vaccine is warranted. We expect to recruit 1-2 HLA A0201+ and 2-3 HLAA2- patients/ month with a follow up of 24 months, allowing completion of the study in the 4 years of funding requested.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>973304</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>International Cancer Immunolgy Conference, New York, Sept 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>33B87B0D-8A73-4B8F-959B-4F3B60F6B4B1</gtr:id><gtr:impact>talk sparked questions and discussion afterwards</gtr:impact><gtr:outcomeId>56cf0242c3c2b4.61403122</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gene Vaccination Conference, Ascoli, Italy Oct 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3AF888C8-0DC1-4931-81E6-9CA50F3C317C</gtr:id><gtr:impact>talk sparked questions and discussions afterwards

unknown</gtr:impact><gtr:outcomeId>54633ed7ac94d0.68261317</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Cancer Vaccines Conference, London Sept 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>56C2BB75-3809-40A2-862A-5D164FE9FB54</gtr:id><gtr:impact>talk sparked questions and discussions afterwards

unknown</gtr:impact><gtr:outcomeId>54633f928c4316.61101922</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Molecular Biology in Cancer Workshop, Birmingham, May 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CF40AC04-13F6-4FE3-B9E4-30E5F935DB45</gtr:id><gtr:impact>talk sparked questions and discussion afterwards</gtr:impact><gtr:outcomeId>56cf01a6502a01.26548505</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Immuno-Oncological Network Ghent Kickoff meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A2382309-4414-4D18-B6F7-38283D91B48A</gtr:id><gtr:impact>I gave a keynote lecture at the inaugural meeting of the immuno-oncology network in Ghen, Belgium. this intends to bring together diverse activities in the immunology and oncology space into a coherent whole for added benefit for the different parties. This included the Belgian cancer charity, industry collaborators and the meeting reached out to national media</gtr:impact><gtr:outcomeId>56dc1fa7ee4846.54919990</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Cancer Vaccines Conference, London Sept 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DFA90C39-87DD-4228-BD20-6F251FF7F051</gtr:id><gtr:impact>talk sparked questions and discussions afterwards

unknown</gtr:impact><gtr:outcomeId>54633f9442f7d2.93942691</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to NIHR Patient Liaison Group  by Gareth Thomas June 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DFF6835C-B58E-48B0-8C91-A338C0ECD531</gtr:id><gtr:impact>talk sparked questions and discussion afterwards

support for continued work</gtr:impact><gtr:outcomeId>546340d5da09a3.01611272</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project Grant (Meso)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Mesothelioma Applied Research Foundation</gtr:fundingOrg><gtr:id>8153D190-B9A9-4DAC-8BF3-9CD76C373F1D</gtr:id><gtr:outcomeId>545b6f2b5d3e05.17268669</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>284857</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CTAP funding (Leukemia and Lymphoma Research)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>AD455698-1C07-437E-AF0F-99B5B4AC65B2</gtr:id><gtr:outcomeId>LrvaES1ELwC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_G1002672</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>